1921
Volume 77, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) infection is known to affect hepatitis C virus (HCV) clearance and to accelerate the development of hepatocellular carcinoma in HCV-infected patients. In this study, we found the prevalence and titer of an antibody recognizing the central region of the HTLV-1 Gp46 protein to be associated with the severity of chronic liver disease. The antibody prevalence was significantly correlated with the stage of chronic liver disease ( < 0.0001): 3 (14.3%) of 21 patients with minimal–mild chronic hepatitis, 12 (24%) of 50 with moderate–severe chronic hepatitis, 7 (87.5%) of 8 with liver cirrhosis, and 13 (100%) of 13 with hepatocellular carcinoma. These results indicate that the antibody may be a useful marker of the deterioration of liver disease in patients co-infected with HCV and HTLV-1. This antibody may be useful for the diagnosis of liver diseases and the development of more effective treatments.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.77.192
2007-07-01
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/1/0770192.html?itemId=/content/journals/10.4269/ajtmh.2007.77.192&mimeType=html&fmt=ahah

References

  1. Franchini G, 1995. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 86 : 3619–3639.
  2. Manns A, Hisada M, La Grenade L, 1999. Human T-lymphotropic virus type I infection. Lancet 353 : 1951–1958.
  3. Yamaguchi K, 1994. Human T-lymphotropic virus type I in Japan. Lancet 343 : 213–216.
  4. Hayashi J, Kishihara Y, Yoshimura E, Furusyo N, Yamaji K, Kawakami Y, Murakami H, Kashiwagi S, 1997. Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. Am J Trop Med Hyg 56 : 71–75.
  5. Tachibana N, Okayama A, Ishizaki J, Yokota T, Shishime E, Murai K, Shioiri S, Tsuda K, Essex M, Mueller N, 1988. Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan. Int J Cancer 42 : 829–831.
  6. Murai K, Tachibana N, Shioiri S, Shishime E, Okayama A, Ishizaki J, Tsuda K, Mueller N, 1990. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr 3 : 1006–1009.
  7. Sagara Y, Inoue Y, Shiraki H, Jinno A, Hoshino H, Maeda Y, 1996. Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides. J Virol 70 : 1564–1569.
  8. Sagara Y, Inoue Y, Tsujimura M, Kojima E, Shiraki H, Kashiwagi S, 2004. Novel biomarker of HTLV-1–associated disease: specific appearance of antibody recognizing the receptor-binding site on HTLV-1 envelope protein. Cancer Sci 95 : 835–839.
  9. Kishihara Y, Furusyo N, Kashiwagi K, Mitsutake A, Kashiwagi S, Hayashi J, 2001. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. J Infect Dis 184 : 1114–1119.
  10. Hayashi J, Furusyo N, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S, 2000. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 181 : 1523–1527.
  11. Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N, 2000. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki. Jpn J Infect Dis 181 : 35–41.
  12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J, 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 : 431–435.
  13. Washitani Y, Kuroda N, Shiraki H, Itoyama Y, Sato H, Ohshima K, Kiyokawa H, Maeda Y, 1992. Linear antigenic regions of the structural proteins of human T-cell lymphotropic virus type I detected by enzyme-linked immunosorbent assays using synthetic peptides as antigens. J Clin Microbiol 30 : 287–290.
  14. Hayashi J, Nakashima K, Kishihara Y, Ohmiya M, Yoshimura E, Hirata M, Kashiwagi S, 1993. Improved detection of antibodies to hepatitis C virus by the second-generation assay in patients with chronic non-A, non-B liver disease. J Infect 26 : 287–294.
  15. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M, 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 : 359–362.
  16. Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S, 1996. Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91 : 314–318.
  17. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, 1992. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73 : 673–679.
  18. Nakashima K, Hayashi J, Hirata M, Kashiwagi S, Eda F, 1994. Hepatitis C virus infection on Iki Island, Japan, an area endemic for human T-lymphotropic virus tpe-1: a preliminary study in patients at clinics or hospitals. J Epidemiol 4 : 17–23.
  19. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, Kashiwagi S, 1995. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90 : 794–799.
  20. Zeldis JB, Jensen P, 1994. Hepatitis C virus pathogenicity: the corner pieces of the jigsaw puzzle are found. Gastroenterology 106 : 1118–1120.
  21. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD, 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 : 1499–1512.
  22. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM, 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 : 659–662.
  23. Kawakami Y, Nabeshima S, Furusyo N, Sawayama Y, Hayashi J, Kashiwagi S, 2000. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am J Gastroenterol 95 : 227–232.
  24. Murata M, Nabeshima S, Maeda N, Nakashima H, Kashiwagi S, Hayashi J, 2002. Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. J Med Virol 67 : 162–170.
  25. Wodarz D, Hall SE, Usuku K, Osame M, Ogg GS, McMichael AJ, Nowak MA, Bangham CR, 2001. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc Biol Sci 268 : 1215–1221.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.192
Loading
/content/journals/10.4269/ajtmh.2007.77.192
Loading

Data & Media loading...

  • Received : 24 Oct 2006
  • Accepted : 15 Jan 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error